Overview of metformin: special focus on metformin extended release
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Diabetes is characterized by chronic hyperglycemia and vascular alterations, leading to micro-vascular and macro-vascular complications, which account for increased morbidity and mortality associated with the disease. Cardiovascular complications are the leading cause of death in patients with diabetes. Due to its cardio-protective effects, metformin is recommended as the initial agent of choice in the treatment of T2DM. Results of UKPDS, one of the largest and longest studies, showed reductions in cardiovascular mortality in patients using metformin. AREAS COVERED: This article reviews the history, structure, pharmacokinetics, clinical efficacy, and safety of extended-release metformin (XR). It also highlights fact that its use has been shown to have the same clinical and metabolic benefits as standard metformin, but also improved adherence and reduced side effects. The paper provides a side-by-side comparison of the main differences in the use of metformin XR versus metformin IR, i.e., their effect on lipids, and gastrointestinal (GI) side effects. Studies included in this review were selected from PUBMED and Embase databases. EXPERT OPINION: Given the chronic nature of diabetes, patient's adherence to therapy is very important in preventing complications of the disease. Compliance with the standard metformin formulation can be poor, due to multiple daily dosing and frequent GI side effects. Metformin XR can be given once daily and is associated with less GI side effects compared to immediate release metformin (IR); This leads to increased compliance, improved glycemic control and hence decreased risk of the associated micro- and macro-vascular complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“In another case control study patients on metformin had 23% reduced risk of cancer compared to patients who were on sulfonylureas [75] Activation of AMPK by metformin not only lowers blood glucose but also suppresses tumor formation and inhibits cell growth.”
BackgroundTurner, R. C. (1999) · JAMA · doi:10.1001/jama.281.21.2005 · Cited by 2,375 · cited 2×
“Treatment of diabetes with metformin is also more effective in reducing weight in people with higher BMI [37]”
BackgroundAdvanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261 · cited 1×
“Hyperglycemia leads to formation of advanced glycation end products (AGEs), which have detrimental effects on endothelium [68,69] Metformin directly binds with glycated products and decreases the concentration of AGEs halting the underlying process in development of atherosclerosis [70,71].”
BackgroundOWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 2×
“Inhibition of the respiratory chain complex inhibits hepatic gluconeogenesis and increases glucose utilization in peripheral tissues [27].”
BackgroundMitochondrial dysfunction and type 2 diabetes
Lowell, B. B., & Shulman, G. I. (2005) · Science · doi:10.1126/science.1104343 · Cited by 2,070
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399 · cited 1×
“of action of metformin in the mitochondria is complex 1 of respiratory chain and activation of AMPK occurs as a secondary effect [26,27] Metformin was reported to cause time and concentration dependent inhibition of complex 1 respiratory chain in isolated rat hepatocytes.”
BackgroundEfficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368 · cited 2×
“Compared with placebo metformin causes statistically significant improvement in LDL-C and increase in HDL-C [58,61,62].”
BackgroundForetz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 6×
“The study explains site of metformin action upstream of AMPK [29].”
BackgroundInfluentialMetabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148 · cited 1×
“High concentration of metformin in liver increases anaerobic metabolism of glucose raising lactate level and can also decrease lactate utilization [84,85] so it should be used with caution in patients Table 1.”
BackgroundNew Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996 · cited 1×
“6% with other hypoglycemic agents in patients with diabetes suggesting metformin use with low cancer risk [76].”
BackgroundBowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Quantitation of Hepatic Glycogenolysis And Gluconeogenesis in Fasting Humans With 13 C NMR
Rothman, D. L., Magnusson, I., Katz, L. D., Shulman, R. G., & Shulman, G. I. (1991) · Science · doi:10.1126/science.1948033 · Cited by 546 · cited 1×
“During fasting, gluconeogenesis by the liver increases which prevents hypoglycemia [13,14] whereas in the post-parandial state, increase in blood glucose stimulates insulin secretion which inhibits glycogenolysis and stimulates glycogen synthesis which keeps blood sugar from rising above normal range [15,16].”
BackgroundGoldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc09-1380 · Cited by 502
Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects
DEFRONZO, R. A., BARZILAI, N., & SIMONSON, D. C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-6-1294 · Cited by 408
Dunn, C. J., & Peters, D. H. (1995) · Drugs · doi:10.2165/00003495-199549050-00007 · Cited by 391
Sensing of energy and nutrients by AMP-activated protein kinase
Hardie, D. G. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.001925 · Cited by 372 · cited 1×
“It has been suggested that Metformin acts through stimulation of AMP-activated protein kinase (AMPK) which acts as fuel gauge or glucose sensor and is activated by an increasing cellular AMP: ATP ratio [23].”
BackgroundPharmacokinetics of Metformin After Intravenous and Oral Administration to Man
Pentik�inen, P. J., Neuvonen, P. J., & Penttil�, A. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562061 · Cited by 348
Risk Factors of Vitamin B12 Deficiency in Patients Receiving Metformin
Ting, R. Z.-W. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.18.1975 · Cited by 333 · cited 1×
“Dose of metformin was shown to be strongest predictor for development of B12 deficiency [83].”
BackgroundAlterations in postprandial hepatic glycogen metabolism in type 2 diabetes.
Krssak, M., Brehm, A., Bernroider, E., Anderwald, C., Nowotny, P., Man, C. D., Cobelli, C., Cline, G. W., Shulman, G. I., Waldhäusl, W., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.12.3048 · Cited by 313 · cited 1×
“During fasting, gluconeogenesis by the liver increases which prevents hypoglycemia [13,14] whereas in the post-parandial state, increase in blood glucose stimulates insulin secretion which inhibits glycogenolysis and stimulates glycogen synthesis which keeps blood sugar from rising above normal range [15,16].”
BackgroundWile, D. J., & Toth, C. (2010) · Diabetes Care · doi:10.2337/dc09-0606 · Cited by 283
Bailey, C. J., Wilcock, C., & Scarpello, J. H. B. (2008) · Diabetologia · doi:10.1007/s00125-008-1053-5 · Cited by 275
Hepatic glucose metabolism in humans—its role in health and disease
Roden, M., & Bernroider, E. (2003) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/s1521-690x(03)00031-9 · Cited by 201
Fujioka, K., Brazg, R. L., Raz, I., Bruce, S., Joyal, S., Swanink, R., & Pans, M. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00369.x · Cited by 73 · cited 3×
“, 2006 [42] At 16 weeks of treatment TGs (mg/dl) Placebo Metformin XR 1000mg/day Metformin XR 1500mg/day (Baseline mean (SD) 212 (252) 212 (198) 198 (155) Mean D vs.”
BackgroundLevy, J., Cobas, R. A., & Gomes, M. B. (2010) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-2-16 · Cited by 44 · cited 4×
“7% 0% Incidence of GI side effects on IR metformin and at 6 months after switchover to XR [1] Diarrhea 58% 14% Nausea 18% 6% S.”
BackgroundInfluential
Cited by
Luchsinger, J. A., Perez, T., Chang, H., Mehta, P., Steffener, J., Pradabhan, G., Ichise, M., Manly, J., Devanand, D. P., & Bagiella, E. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150493 · Cited by 285
“A potential way to improve tolerance and achievement of the maximum dose is to use long-acting forms of metformin [93] instead of the short acting form that we used.”
Rickels, M. R., Bellin, M., Toledo, F. G. S., Robertson, R. P., Andersen, D. K., Chari, S. T., Brand, R., Frulloni, L., Anderson, M. A., & Whitcomb, D. C. (2013) · Pancreatology · doi:10.1016/j.pan.2013.05.002 · Cited by 249
New Insights Into the Anti-Diabetic Actions of Metformin: From the Liver to the Gut
Wu, T., Horowitz, M., & Rayner, C. K. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1273769 · Cited by 64
“immediate-, extended-, and delayed-release metformin), nausea and vomiting appear to be less with extended- and delayed-release, than with immediate-release formulations [53,81], which may reflect a lesser increment in plasma metformin concentrations after oral administration.”
BackgroundInstituting a successful discharge plan for patients with type 2 diabetes: challenges and solutions
Demidowich, A. P., Batty, K., & Zilbermint, M. (2022) · Diabetes Spectrum · doi:10.2337/dsi22-0013 · Cited by 15
Bock, B. C., Dunsiger, S. I., Wu, W.-C., Ciccolo, J. T., Serber, E. R., Lantini, R., & Marcus, B. H. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.06.011 · Cited by 6
“More importantly, in this study increased physical activity by way of EVGs was able to achieve results similar to pharmacotherapy without the side effects associated with the anti-diabetes medications [34].”
Background
Metadata
- Authors
- Ali, S., & Fonseca, V.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2012-07-09
- Volume
- 13
- Issue
- 12
- Pages
- 1797-1805
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2148509846
- Cited by
- 66
- References
- 26
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.